Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Inactivation of p53 and Pten promotes invasive bladder cancer.

Puzio-Kuter AM, Castillo-Martin M, Kinkade CW, Wang X, Shen TH, Matos T, Shen MM, Cordon-Cardo C, Abate-Shen C.

Genes Dev. 2009 Mar 15;23(6):675-80. doi: 10.1101/gad.1772909. Epub 2009 Mar 4.

2.

Regulator of cullins-1 expression knockdown suppresses the malignant progression of muscle-invasive transitional cell carcinoma by regulating mTOR/DEPTOR pathway.

Wang W, Chen H, Liu Z, Qu P, Lan J, Chen H, Zou L, Qiu J.

Br J Cancer. 2016 Feb 2;114(3):305-13. doi: 10.1038/bjc.2015.444. Epub 2016 Jan 7.

3.
4.

Intravesical delivery of rapamycin suppresses tumorigenesis in a mouse model of progressive bladder cancer.

Seager CM, Puzio-Kuter AM, Patel T, Jain S, Cordon-Cardo C, Mc Kiernan J, Abate-Shen C.

Cancer Prev Res (Phila). 2009 Dec;2(12):1008-14. doi: 10.1158/1940-6207.CAPR-09-0169. Epub 2009 Dec 1.

5.

Alterations of mTOR and PTEN protein expression in schistosomal squamous cell carcinoma and urothelial carcinoma.

Makboul R, Refaiy A, Abdelkawi IF, Hameed DA, Elderwy AA, Shalaby MM, Merseburger AS, Hussein MR.

Pathol Res Pract. 2016 May;212(5):385-92. doi: 10.1016/j.prp.2016.02.008. Epub 2016 Feb 9.

PMID:
26916953
6.

Hyperplasia and carcinomas in Pten-deficient mice and reduced PTEN protein in human bladder cancer patients.

Tsuruta H, Kishimoto H, Sasaki T, Horie Y, Natsui M, Shibata Y, Hamada K, Yajima N, Kawahara K, Sasaki M, Tsuchiya N, Enomoto K, Mak TW, Nakano T, Habuchi T, Suzuki A.

Cancer Res. 2006 Sep 1;66(17):8389-96.

7.

Dysregulation of mammalian target of rapamycin pathway in plasmacytoid variant of urothelial carcinoma of the urinary bladder.

Gonzalez-Roibon ND, Chaux A, Al-Hussain T, Osunkoya AO, Bezerra SM, Hicks J, Epstein JI, Netto GJ.

Hum Pathol. 2013 Apr;44(4):612-22. doi: 10.1016/j.humpath.2012.07.009. Epub 2012 Oct 17.

8.

Canine invasive transitional cell carcinoma cell lines: in vitro tools to complement a relevant animal model of invasive urinary bladder cancer.

Dhawan D, Ramos-Vara JA, Stewart JC, Zheng R, Knapp DW.

Urol Oncol. 2009 May-Jun;27(3):284-92. doi: 10.1016/j.urolonc.2008.02.015. Epub 2008 Jun 18.

PMID:
18562222
9.

Targeting mTOR and p53 Signaling Inhibits Muscle Invasive Bladder Cancer In Vivo.

Madka V, Mohammed A, Li Q, Zhang Y, Biddick L, Patlolla JM, Lightfoot S, Towner RA, Wu XR, Steele VE, Kopelovich L, Rao CV.

Cancer Prev Res (Phila). 2016 Jan;9(1):53-62. doi: 10.1158/1940-6207.CAPR-15-0199. Epub 2015 Nov 17.

10.

p53-stabilizing agent CP-31398 prevents growth and invasion of urothelial cancer of the bladder in transgenic UPII-SV40T mice.

Madka V, Zhang Y, Li Q, Mohammed A, Sindhwani P, Lightfoot S, Wu XR, Kopelovich L, Rao CV.

Neoplasia. 2013 Aug;15(8):966-74.

11.

Differential PTEN protein expression profiles in superficial versus invasive bladder cancers.

Koksal IT, Yasar D, Dirice E, Usta MF, Karauzum S, Luleci G, Baykara M, Sanlioglu S.

Urol Int. 2005;75(2):102-6.

PMID:
16123561
12.
13.

Biology of urothelial tumorigenesis: insights from genetically engineered mice.

Wu XR.

Cancer Metastasis Rev. 2009 Dec;28(3-4):281-90. doi: 10.1007/s10555-009-9189-4. Review.

14.

microRNA-21 Regulates Cell Proliferation and Migration and Cross Talk with PTEN and p53 in Bladder Cancer.

Lei M, Xie W, Sun E, Sun Y, Tian D, Liu C, Han R, Li N, Liu M, Han R, Liu L.

DNA Cell Biol. 2015 Oct;34(10):626-32. doi: 10.1089/dna.2015.2868. Epub 2015 Jul 31.

PMID:
26230405
15.

Significance of 4E-binding protein 1 as a therapeutic target for invasive urothelial carcinoma of the bladder.

Nishikawa M, Miyake H, Behnsawy HM, Fujisawa M.

Urol Oncol. 2015 Apr;33(4):166.e9-15. doi: 10.1016/j.urolonc.2014.12.006. Epub 2015 Jan 21.

PMID:
25618298
16.

Genetic and immunophenotype analyses of TP53 in bladder cancer: TP53 alterations are associated with tumor progression.

Erill N, Colomer A, Verdú M, Román R, Condom E, Hannaoui N, Banús JM, Cordon-Cardo C, Puig X.

Diagn Mol Pathol. 2004 Dec;13(4):217-23.

PMID:
15538112
17.

Loss of p53 and acquisition of angiogenic microRNA profile are insufficient to facilitate progression of bladder urothelial carcinoma in situ to invasive carcinoma.

Ayala de la Peña F, Kanasaki K, Kanasaki M, Tangirala N, Maeda G, Kalluri R.

J Biol Chem. 2011 Jun 10;286(23):20778-87. doi: 10.1074/jbc.M110.198069. Epub 2011 Mar 9.

18.

PTEN deficiency accelerates tumour progression in a mouse model of thyroid cancer.

Guigon CJ, Zhao L, Willingham MC, Cheng SY.

Oncogene. 2009 Jan 29;28(4):509-17. doi: 10.1038/onc.2008.407. Epub 2008 Nov 10.

19.

A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.

Korkolopoulou P, Levidou G, Trigka EA, Prekete N, Karlou M, Thymara I, Sakellariou S, Fragkou P, Isaiadis D, Pavlopoulos P, Patsouris E, Saetta AA.

BJU Int. 2012 Dec;110(11 Pt C):E1237-48. doi: 10.1111/j.1464-410X.2012.11569.x. Epub 2012 Oct 29.

20.

The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer.

Smith ND, Rubenstein JN, Eggener SE, Kozlowski JM.

J Urol. 2003 Apr;169(4):1219-28. Review.

PMID:
12629332

Supplemental Content

Support Center